Samsung Biologics Co., Ltd. (207940)
KRX
1,585,000.00
+12,000.00 (+0.76%)
Closed
Aug 25, 2026
Day's Range
1,537,000.001,596,000.00
52 wk Range
1,228,000.001,987,000.00
Financial Statements - 207940 - Samsung Biologics Co., Ltd.
Revenue
4.55T▲ 0.2%
Net Income
1.78T▲ 64.7%Net Margin 39.2%
EBITDA
2.79T▲ 35.1%
Free Cash Flow
772.73B▲ 174.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 4.55T | 4.54T | 3.69T | 3T | 1.56T | 1.16T |
| Cost of Goods | 2.04T | 2.25T | 1.89T | 1.53T | 841.55B | 748.70B |
| Gross Profit | 2.51T | 2.29T | 1.80T | 1.46T | 726.45B | 416.07B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 2.06T | 1.32T | 1.11T | 983.62B | 537.30B | 292.78B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 2.11T | 1.37T | 1.11T | 1T | 561.28B | 265.99B |
| Income Tax | 504.30B | 286.73B | 262.29B | 210.96B | 167.69B | 25.01B |
| Net Income | 1.78T | 1.08T | 857.69B | 798.05B | 393.58B | 240.97B |
| EPS Basic | 26.62K | 15.22K | 12.05K | 11.44K | 5.88K | 3.60K |
| EPS Diluted | 26.62K | 15.22K | 12.05K | 11.43K | 5.88K | 3.60K |
| Basic Shares Outstanding | - | 71.17M | 71.17M | 69.74M | 66.86M | 66.86M |
| Diluted Shares Outstanding | - | 71.17M | 71.17M | 69.74M | 66.86M | 66.86M |
| Ebit | 2.14T | 1.42T | 1.20T | 1.07T | 575.98B | 282.07B |
| Ebitda | 2.79T | 2.06T | 1.69T | 1.30T | 740.67B | 431.16B |
| Net Income Continuous Operations | 1.78T | 1.08T | 857.69B | 798.05B | 393.58B | 240.97B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
